<DOC>
	<DOCNO>NCT00172055</DOCNO>
	<brief_summary>The objective study investigate whether blood marker use predict development bone metastases assess efficacy safety zoledronic acid cancer treatment induce bone loss .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Zoledronic Acid Value Markers Bone Resorption Prediction Bone Metastases Cancer Treatment-induced Bone Loss ( CTIBL ) Patients With Prostate Cancer Hormone Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bone Resorption</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>All stage prostate cancer without bone metastases No evidence severe osteoporosis ECOG performance status 0 , 1 2 Surgery / fracture lumbosacral spine , bilateral hip implant Evidence metabolic bone disease , Treatment bisphosphonates calcitonin within previous year chronic systemic corticosteroid treatment Abnormal kidney liver function Other cancer within last 5 year Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Zoledronic acid</keyword>
	<keyword>Zometa</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>osteoporosis</keyword>
</DOC>